NASDAQ:EDIT - Editas Medicine Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $54.00
  • Forecasted Upside: -29.08 %
  • Number of Analysts: 8
  • Breakdown:
  • 1 Sell Ratings
  • 4 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$76.14
▲ +0.22 (0.29%)
1 month | 3 months | 12 months
Get New Editas Medicine Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for EDIT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for EDIT

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$54.00
▼ -29.08% Downside Potential
This price target is based on 8 analysts offering 12 month price targets for Editas Medicine in the last 3 months. The average price target is $54.00, with a high forecast of $86.00 and a low forecast of $14.00. The average price target represents a -29.08% upside from the last price of $76.14.
Hold
The current consensus among 8 polled investment analysts is to hold stock in Editas Medicine. This rating has held steady since February 2020, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 5 buy ratings
  • 4 hold ratings
  • 0 sell ratings
7/28/2019
  • 0 strong buy ratings
  • 5 buy ratings
  • 3 hold ratings
  • 0 sell ratings
10/26/2019
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
1/24/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 4 hold ratings
  • 0 sell ratings
4/23/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 4 hold ratings
  • 0 sell ratings
7/22/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 4 hold ratings
  • 0 sell ratings
10/20/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 4 hold ratings
  • 1 sell ratings
12/19/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 4 hold ratings
  • 1 sell ratings
1/18/2021

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 4 hold ratings
  • 1 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/13/2021Wells Fargo & CompanyBoost Price TargetOverweight$69.00 ➝ $86.00Medium
i
1/7/2021Raymond JamesDowngradeOutperform ➝ Market PerformN/A
i
12/16/2020Morgan StanleyBoost Price TargetEqual Weight$30.00 ➝ $64.00Low
i
12/10/2020Wells Fargo & CompanyUpgradeEqual Weight ➝ Overweight$28.00 ➝ $69.00High
i
11/11/2020Morgan StanleyLower Price TargetEqual Weight$31.00 ➝ $30.00High
i
11/6/2020Raymond JamesLower Price TargetOutperform$65.00 ➝ $60.00Medium
i
11/2/2020Robert W. BairdInitiated CoverageUnderperform$14.00High
i
10/13/2020Morgan StanleyLower Price TargetEqual Weight$32.00 ➝ $31.00Medium
i
8/10/2020Morgan StanleyBoost Price TargetEqual Weight$27.00 ➝ $32.00Low
i
8/7/2020Raymond JamesBoost Price TargetOutperform$46.00 ➝ $65.00High
i
6/18/2020SunTrust BanksInitiated CoverageBuy$45.00High
i
6/15/2020OppenheimerReiterated RatingHoldHigh
i
Rating by Silvan Tuerkcan at Oppenheimer Holdings Inc.
6/12/2020Chardan CapitalReiterated RatingBuy$55.00High
i
Rating by Geulah Livshits at Chardan Capital
5/11/2020Morgan StanleyLower Price TargetEqual Weight$30.00 ➝ $27.00High
i
5/7/2020OppenheimerInitiated CoverageHoldMedium
i
Rating by Silvan Tuerkcan at Oppenheimer Holdings Inc.
3/4/2020Chardan CapitalReiterated RatingBuy$55.00High
i
Rating by Geulah Livshits at Chardan Capital
2/27/2020Raymond JamesLower Price TargetOutperform$44.00 ➝ $41.00High
i
2/27/2020JPMorgan Chase & Co.Reiterated RatingHoldHigh
i
2/21/2020Wells Fargo & CompanyInitiated CoverageEqual Weight$28.00High
i
12/10/2019Chardan CapitalReiterated RatingBuy$55.00Low
i
Rating by Geulah Livshits at Chardan Capital
8/9/2019Morgan StanleySet Price TargetHold$29.00High
i
Rating by Matthew Harrison at Morgan Stanley
7/25/2019Chardan CapitalReiterated RatingBuy$55.00Medium
i
Rating by Geulah Livshits at Chardan Capital
6/16/2019Chardan CapitalSet Price TargetBuy$55.00Medium
i
Rating by Geulah Livshits at Chardan Capital
5/8/2019OppenheimerReiterated RatingHoldMedium
i
Rating by Silvan Tuerkcan at Oppenheimer Holdings Inc.
4/11/2019Evercore ISIInitiated CoverageOutperformMedium
i
2/7/2019BTIG ResearchInitiated CoverageBuy$30.00Low
i
1/22/2019JPMorgan Chase & Co.Reiterated RatingHoldHigh
i
Rating by Cory Kasimov at JPMorgan Chase & Co.
1/22/2019CowenReiterated RatingBuyMedium
i
1/22/2019Chardan CapitalReiterated RatingBuy$55.00High
i
1/10/2019JPMorgan Chase & Co.Reiterated RatingHoldLow
i
Rating by Cory Kasimov at JPMorgan Chase & Co.
12/31/2018SunTrust BanksReiterated RatingBuyHigh
i
10/9/2018GuggenheimInitiated CoverageNeutral ➝ NeutralHigh
i
Rating by Whitney Ijem at Guggenheim
9/21/2018Raymond JamesInitiated CoverageOutperform ➝ Outperform$40.00High
i
8/6/2018JPMorgan Chase & Co.Set Price TargetHold$36.00High
i
Rating by Cory Kasimov at JPMorgan Chase & Co.
5/15/2018Chardan CapitalLower Price TargetBuy$72.50 ➝ $55.00Low
i
3/14/2018Morgan StanleyReiterated RatingEqual Weight ➝ Equal Weight$28.00 ➝ $43.00Low
i
3/7/2018BarclaysBoost Price TargetOverweight ➝ Overweight$28.00 ➝ $46.00Medium
i
3/7/2018JMP SecuritiesBoost Price TargetOutperform$40.00 ➝ $67.00High
i
2/13/2018CLSAInitiated CoverageUnderperform ➝ UnderperformLow
i
1/23/2018SunTrust BanksUpgradeHold ➝ Buy$17.00 ➝ $45.00High
i
11/7/2017CowenReiterated RatingBuyN/A
i
10/6/2017Morgan StanleyReiterated RatingEqual Weight$27.00 ➝ $28.00N/A
i
9/6/2017BarclaysInitiated CoverageOverweight$19.69 ➝ $28.00Medium
i
8/9/2017JPMorgan Chase & Co.Set Price TargetHold$27.00High
i
Rating by Cory Kasimov at JPMorgan Chase & Co.
7/18/2017OppenheimerMarket PerformN/A
i
7/13/2017SunTrust BanksInitiated CoverageHold ➝ Hold$17.00High
i
3/27/2017Chardan CapitalInitiated CoverageBuy ➝ BuyHigh
i
3/15/2017CowenReiterated RatingBuyLow
i
3/8/2017JPMorgan Chase & Co.Set Price TargetHold$32.00Low
i
Rating by Cory Kasimov at JPMorgan Chase & Co.
2/19/2017JPMorgan Chase & Co.Reiterated RatingHoldN/A
i
2/15/2017Jefferies Financial GroupReiterated RatingBuy$35.00N/A
i
Rating by Gena Wang at Jefferies Financial Group Inc.
1/11/2017Jefferies Financial GroupSet Price TargetBuy$35.00N/A
i
Rating by Gena Wang at Jefferies Financial Group Inc.
12/12/2016Jefferies Financial GroupSet Price TargetBuy$35.00N/A
i
Rating by Gena Wang at Jefferies Financial Group Inc.
8/22/2016Jefferies Financial GroupReiterated RatingBuyN/A
i
Rating by Gena Wang at Jefferies Financial Group Inc.
8/10/2016Jefferies Financial GroupUpgradeHold ➝ Buy$35.00N/A
i
Rating by Gena Wang at Jefferies Financial Group Inc.
6/10/2016Jefferies Financial GroupReiterated RatingHold$35.00N/A
i
Rating by Gena Wang at Jefferies Financial Group Inc.
6/2/2016Jefferies Financial GroupInitiated CoverageHold$35.00N/A
i
5/16/2016CowenReiterated RatingBuyN/A
i
Rating by Phil Nadeau at Cowen Inc
2/29/2016Morgan StanleyInitiated CoverageEqual ➝ Equal Weight$28.00N/A
i
2/29/2016JPMorgan Chase & Co.Initiated CoverageNeutral$32.00N/A
i
2/29/2016JMP SecuritiesInitiated CoverageOutperform$40.00N/A
i
2/29/2016CowenInitiated CoverageOutperformN/A
i
(Data available from 1/18/2016 forward)
Editas Medicine logo
Editas Medicine, Inc. operates as a clinical stage genome editing company. The company focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary genome editing platform based on CRISPR technology, which includes CRISPR/Cas9, CRISPR/Cas12a, and engineered forms of both of these CRISPR systems to target genetically addressable diseases and therapeutic areas. It also develops EDIT-101, which is in Phase 1/2 clinical trial for the treatment of Leber Congenital Amaurosis type 10, a genetic form of vision loss that leads to blindness in childhood. In addition, the company develops EDIT-102 for the treatment of Usher Syndrome 2A, which is a form of retinitis pigmentosa that also includes hearing loss; autosomal dominant retinitis pigmentosa 4, a progressive form of retinal degeneration; and EDIT-301 treat sickle cell disease and beta-thalassemia. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited to discover, develop, and commercialize new gene editing medicines for a range of ocular disorders; strategic research collaboration Asklepios BioPharmaceutical, Inc. to develop a therapy to treat a neurological disease; and research collaboration with Sandhill Therapeutics, Inc. to develop allogeneic healthy donor derived NK cell medicines for the treatment of solid tumors. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $76.14
$76.06
$83.84

50 Day Range

MA: $64.43
$30.59
$90.58

52 Week Range

Now: $76.14
$14.01
$99.95

Volume

191,022 shs

Average Volume

3,012,330 shs

Market Capitalization

$4.75 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.1

Frequently Asked Questions

What sell-side analysts currently cover shares of Editas Medicine?

The following Wall Street analysts have issued reports on Editas Medicine in the last year: Chardan Capital, JPMorgan Chase & Co., Morgan Stanley, Oppenheimer Holdings Inc., Raymond James, Robert W. Baird, SunTrust Banks, Inc., Wells Fargo & Company, and Zacks Investment Research.

What is the current price target for Editas Medicine?

6 Wall Street analysts have set twelve-month price targets for Editas Medicine in the last year. Their average twelve-month price target is $54.00, suggesting a possible downside of 29.1%. Wells Fargo & Company has the highest price target set, predicting EDIT will reach $86.00 in the next twelve months. Robert W. Baird has the lowest price target set, forecasting a price of $14.00 for Editas Medicine in the next year.

What is the current consensus analyst rating for Editas Medicine?

Editas Medicine currently has 1 sell rating, 4 hold ratings and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in EDIT, but not buy more shares or sell existing shares.

What other companies compete with Editas Medicine?

How do I contact Editas Medicine's investor relations team?

Editas Medicine's physical mailing address is 11 Hurley Street, Cambridge MA, 02141. The company's listed phone number is 617-401-9000 and its investor relations email address is mark.mullikin@editasmed.com. The official website for Editas Medicine is www.editasmedicine.com.